Schrödinger, Inc.
SDGRHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeSchrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the. With a market capitalization of $1.14B, it sits in small-cap territory. The company operates in two segments, Software and Drug Discovery.
Market Cap
$1.14B
Beta
1.62
P/E (TTM)
—
P/E (Fwd)
-9.23
EPS (TTM)
$-1.40
EPS (Fwd)
$-1.66
ROE
-30.1%
ROA
-15.0%
Cash
$399.0M
Total Debt
$107.0M
Free CF
-$49.4M
52W Change
-28.6%
Annual Financials
Cash vs Debt
Schrödinger, Inc. holds $399.0M in cash against $107.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$49.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -30.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $181.0M (2022) to $255.9M (2025), reflecting a 41% increase over the period.
With a beta above 1.5, SDGR tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, SDGR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SDGR.